<i>In Vivo</i> Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials
Kurt Selle, Joshua R. Fletcher, Hannah H. Tuson, Daniel Schmitt, Lana McMillan, Gowrinarayani S. Vridhambal, Alissa J. Rivera, Stephanie A. Montgomery, Louis‐Charles Fortier, Rodolphe Barrangou, Casey M. Theriot, David G. Ousterout
Abstract
Clostridioides difficile is a bacterial pathogen responsible for significant morbidity and mortality across the globe. Current therapies based on broad-spectrum antibiotics have some clinical success, but approximately 30% of patients have relapses, presumably due to the continued perturbation to the gut microbiota. Here, we show that phages can be engineered with type I CRISPR-Cas systems and modified to reduce lysogeny and to enable the specific and efficient targeting and killing of C. difficile in vitro and in vivo. Additional genetic engineering to disrupt phage modulation of toxin expression by lysogeny or other mechanisms would be required to advance a CRISPR-enhanced phage antimicrobial for C. difficile toward clinical application. These findings provide evidence into how phage can be combined with CRISPR-based targeting to develop novel therapies and modulate microbiomes associated with health and disease.